Leonid Pavlovich Churilov

Dr. Leonid Pavlovich Churilov

Laboratory of the Mosaic of Autoimmunity, Saint Petersburg State University, 199034 Saint Petersburg, Russia

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Best Practice & Research Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
FRFrancesca Ragusa
Francesca Ragusa
PFPoupak Fallahi
Poupak Fallahi
GEGiusy Elia
Giusy Elia
DGDebora Gonnella
Debora Gonnella
SPSabrina Rosaria Paparo
Sabrina Rosaria Paparo
Alessandro AntonelliAlessandro Antonelli
Alessandro Antonelli

1 February 2021 in Clinical Immunology
Verified
Journal Article
Closed access
VRVarvara A. Ryabkova
Varvara A. Ryabkova
Leonid ChurilovLeonid Churilov
Leonid Churilov
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld

1 December 2019 in Best Practice & Research Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
Leonid ChurilovLeonid Churilov
Leonid Churilov
PSPolina A. Sobolevskaia
Polina A. Sobolevskaia
YSYuri I. Stroev
Yuri I. Stroev

25 February 2021 in Antibodies
Verified
Journal Article
Open access
PDF file
IPIrina Pashnina
Irina Pashnina
IKIrina Krivolapova
Irina Krivolapova
TFTamara Viktorovna Fedotkina
Tamara Viktorovna Fedotkina
YSYehuda Shoenfeld
Yehuda Shoenfeld
MCMargarita Chereshneva
Margarita Chereshneva
VCValeriy Chereshnev
Valeriy Chereshnev
The incidence of autoimmune diseases is increasing. Antinuclear antibody (ANA) testing is a critical tool for their diagnosis. However, ANA prevalence in healthy persons has increased over the last decades, especially among young people. ANA in health occurs in low concentrations, with a prevalence up to 50% in some populations, which demands a cutoff revision. This review deals with the origin and probable physiological or compensatory function of ANA in health, according to the concept of immunological clearance, theory of autoimmune regulation of cell functions, and the concept of functional autoantibodies. Considering ANA titers ≤1:320 as a serological marker of autoimmune diseases seems inappropriate. The role of anti-DFS70/LEDGFp75 autoantibodies is highlighted as a possible anti-risk biomarker for autoimmune rheumatic disorders. ANA prevalence in health is different in various regions due to several underlying causes discussed in the review, all influencing additive combinations according to the concept of the mosaic of autoimmunity. Not only are titers, but also HEp-2 IFA) staining patterns, such as AC-2, important. Accepting autoantibodies as a kind of bioregulator, not only the upper, but also the lower borders of their normal range should be determined; not only their excess, but also a lack of them or “autoimmunodeficiency” could be the reason for disorders.

Verified
Journal Article
Open access
PDF file
YSYehuda Shoenfeld
Yehuda Shoenfeld
Leonid ChurilovLeonid Churilov
Leonid Churilov
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
Fibromyalgia is a disorder characterized by chronic widespread pain and non-pain symptoms, such as fatigue, dysautonomia, and cognitive and sleep disturbances. Its pathogenesis and treatment continue to be the subject of debate. We highlight the role of three mechanisms—autoimmunity, neuroinflammation, and small fiber neuropathy—in the pathogenesis of the disease. These mechanisms are shown to be closely interlinked (also on a molecular level), and the review considers the implementation of this relationship in the search for therapeutic options. We also pay attention to chronic fatigue syndrome, which overlaps with fibromyalgia, and propose a concept of “autoimmune hypothalamopathy” for its pathogenesis. Finally, we analyze the molecular mechanisms underlying the neuroinflammatory background in the development of adverse events following HPV vaccination and suggesting neuroinflammation, which could exacerbate the development of symptoms following HPV vaccination (though this is hotly debated), as a model for fibromyalgia pathogenesis.

25 August 2022 in Pathophysiology
Verified
Journal Article
Open access
PDF file
Leonid ChurilovLeonid Churilov
Leonid Churilov
Muslimbek G. NormatovMuslimbek G. Normatov
Muslimbek G. Normatov
VUVLADIMIR UTEKHIN
VLADIMIR UTEKHIN
Molecular mimicry between human and microbial/viral/parasite peptides is common and has long been associated with the etiology of autoimmune disorders provoked by exogenous pathogens. A growing body of evidence accumulated in recent years suggests a strong correlation between SARS-CoV-2 infection and autoimmunity. The article analyzes the immunogenic potential of the peptides shared between the SARS-CoV-2 spike glycoprotein (S-protein) and antigens of human endocrinocytes involved in most common autoimmune endocrinopathies. A total of 14 pentapeptides shared by the SARS-CoV-2 S-protein, thyroid, pituitary, adrenal cortex autoantigens and beta-cells of the islets of Langerhans were identified, all of them belong to the immunoreactive epitopes of SARS-CoV-2. The discussion of the findings relates the results to the clinical correlates of COVID-19-associated autoimmune endocrinopathies. The most common of these illnesses is an autoimmune thyroid disease, so the majority of shared pentapeptides belong to the marker autoantigens of this disease. The most important in pathogenesis of severe COVID-19, according to the authors, may be autoimmunity against adrenals because their adequate response prevents excessive systemic action of the inflammatory mediators causing cytokine storm and hemodynamic shock. A critique of the antigenic mimicry concept is given with an assertion that peptide sharing is not a guarantee but only a prerequisite for provoking autoimmunity based on the molecular mimicry. The latter event occurs in carriers of certain HLA haplotypes and when a shared peptide is only used in antigen processing